A Randomized Controlled Trial Comparing the Effectiveness and Safety of Topical Tacrolimus 0.03% Versus Crisaborole 2% in Patients With Mild to Moderate Atopic Dermatitis Over 8 Weeks
Starting soon · Not applicable
Conditions studied: Atopic Dermatitis
In brief
This randomized controlled trial compares the effectiveness and safety of topical tacrolimus 0.03% and crisaborole 2% in patients with mild to moderate atopic dermatitis over 8 weeks. Atopic dermatitis is a chronic inflammatory skin condition affecting quality of life, and steroid-sparing treatments are increasingly preferred due to adverse effects of long-term corticosteroid use. Tacrolimus, a calcineurin inhibitor, and crisaborole, a PDE-4 inhibitor, are both effective alternatives, though tacrolimus may offer greater efficacy while crisaborole has better tolerability. The study will include 70 patients aged 2-20 years, randomized into two groups receiving either treatment. Outcomes will be assessed using EASI score reduction and adverse effects. Data will be analyzed statistically to determine significance. The study aims to generate local evidence to guide treatment decisions and improve management strategies for atopic dermatitis in the Pakistani population.
Key facts
- Study ID
- NCT07519174
- Run by
- Foundation University Islamabad
- People needed
- 72
- Starts
- 2026-06-01
- Expected to finish
- 2027-01-01
- Last updated by the study team
- 2026-04-09
Who can join
Age: 2 and older, up to 20. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 2-20 years Clinically diagnosed mild to moderate AD EASI score ≤21 Informed consent
You may not qualify if…
- Severe AD (EASI \>21) Use of topical/systemic corticosteroids within 2 weeks Secondary infection Known drug hypersensitivity Immunocompromised state
Where it is running
- Fauji Foundation Hospital, Rawalpindi — Rawalpindi, Punjab Province, Pakistan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.